2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2021
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series
Blow T, Hyde PN, Falcone JN, Neinstein A, Vasan N, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integrative Cancer Therapies 2021, 20: 15347354211032283. PMID: 34259084, PMCID: PMC8283040, DOI: 10.1177/15347354211032283.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerSodium-glucose co-transporter-2 inhibitorsLow-carbohydrate dietCase seriesCarbohydrate dietHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Sodium-Glucose CoTransporter 2 inhibitorsTarget adverse effectsFactor receptor 2Postmenopausal womenTreatment delayPharmacologic interventionsBreast cancerDose reductionReceptor 2HyperglycemiaTreatment efficacyHormone receptorsAdverse effectsAlpelisibSelective phosphatidylinositolTherapy
2017
Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.
Stiff A, McQuinn C, Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Ramaswamy B, Carson W. Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer. Journal Of Clinical Oncology 2017, 35: e12126-e12126. DOI: 10.1200/jco.2017.35.15_suppl.e12126.Peer-Reviewed Original ResearchNeo-adjuvant chemotherapyCD8 T cellsCD4 T cellsMore CD8 T cellsT cellsBreast cancerReceptor expressionCheckpoint inhibitorsCheckpoint expressionComplete pathologic response rateMore CD4 T cellsHormone receptorsPathologic response rateClinical stage IOperable breast cancerImmune checkpoint expressionReceptor expression changesBC subgroupsNeoadjuvant chemotherapyClinical responseProspective trialImmune checkpointsMedian agePD-1CTLA-4
2011
PD10-01: Prevalence of Dysfunctional Fanconi Anemia (FA) DNA Repair Pathway in Breast Cancer.
Ramaswamy B, Srividya V, Mullins D, Carothers S, Young G, Wenrui D, Zhao W, Lustberg M, Leon M, Weslowski R, Layman R, Mrozek E, Shapiro C, Villalona-Calero M. PD10-01: Prevalence of Dysfunctional Fanconi Anemia (FA) DNA Repair Pathway in Breast Cancer. Cancer Research 2011, 71: pd10-01-pd10-01. DOI: 10.1158/0008-5472.sabcs11-pd10-01.Peer-Reviewed Original ResearchDNA repair pathwaysFA defectRepair pathwaysFanconi anemia DNA repair pathwayFA DNA repair pathwayHormone receptorsAssociated gene productsRepair fociFA pathwayGene productsCellular responsesMolecular markersFA networkDNA damagePathway defectsPathwayImmuno-fluorescence testADP-ribose polymerase inhibitorsFunctional defectsCommon pathwayFluorescence microscopeMolecular subtypesBreast tumorsTumor cellsFANCD2